Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-Pertuis

At Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-Pertuis, the Service des Maladies respiratoires supports a strong portfolio in respiratory tract diseases and neoplasms, especially asthma, chronic obstructive pulmonary disease, and multiple forms of lung cancer. These studies are mainly designed to test new treatments, improve symptom control, and better understand long-term disease management in patients with complex respiratory illness.

• Severe asthma and COPD research focused on reducing exacerbations and improving day-to-day control
• Studies in advanced and early-stage non-small cell lung cancer, including biomarker-driven and immunotherapy-based approaches
• Trials in rarer thoracic cancers such as small cell lung cancer and pleural mesothelioma
• Evaluation of combination treatments to improve survival and disease control in lung malignancies

This area reflects a broad effort to advance both cancer care and chronic respiratory treatment, with a clear emphasis on therapies that may improve outcomes for patients seen at the site.

The site also contributes to cardiovascular diseases research, with studies addressing rhythm disorders, stroke care, and prevention of embolic complications. The main focus is to evaluate whether new treatment strategies can reduce cardiovascular risk, protect heart function, and improve recovery after serious vascular events.

• Prevention of stroke and peripheral embolism in patients with atrial ectopy or short atrial runs
• Research on frequent premature ventricular contractions and their impact on left ventricular function
• Acute stroke studies for people with large ischemic strokes and limited treatment options
• Assessment of therapies aimed at improving outcomes in patients with cardiac rhythm abnormalities

These trials combine prevention and acute care questions, showing interest in both long-term cardiovascular protection and urgent treatment decisions.

Research in digestive system diseases at this hospital includes colon cancer and colon carcinoma, with a particular interest in treatment planning for older adults. The studies are designed to refine cancer therapy, improve disease-free survival, and better tailor care after surgery or during first-line treatment.

• Trials testing whether pre-surgical treatment can improve outcomes in locally advanced colon cancer
• Studies using biomarkers such as circulating tumor DNA to guide post-operative treatment decisions
• Research on treatment strategies after stage III colorectal cancer resection in older patients
• Evaluation of adjuvant approaches to reduce relapse risk after surgery

This work aims to personalize colorectal cancer care while keeping treatment intensity aligned with patient risk and age.

The site has an active role in hemic and lymphatic diseases, including acute lymphoblastic leukemia, multiple myeloma, and other onco-hematology conditions. These trials are focused on improving survival, refining frontline treatment, and evaluating better strategies for relapsed or high-risk disease.

• Frontline treatment studies in acute lymphoblastic leukemia for younger adults
• Research in multiple myeloma comparing treatment duration and effectiveness in relapse settings
• Assessment of new immunotherapy combinations in blood cancers
• Trials aimed at improving disease control and reducing the need for more intensive procedures

These studies reflect a strong interest in modern blood cancer care, especially approaches that may improve outcomes while making treatment more targeted.

Clinical research in immune system diseases and musculoskeletal diseases includes polymyalgia rheumatica, gout, and related inflammatory conditions. The purpose of these trials is to compare treatment options, reduce inflammation, and find safer ways to control symptoms in patients with chronic or recurrent disease.

• Trials in polymyalgia rheumatica evaluating disease control and steroid-sparing treatment strategies
• Studies for gout attacks in patients with kidney disease or transplantation
• Research assessing the balance between symptom relief and long-term safety in inflammatory disorders
• Work aimed at improving treatment tolerance in patients with complex comorbidities

This therapeutic area highlights the site’s interest in practical, patient-centered care for inflammatory and rheumatic disease.

The nervous system diseases portfolio includes stroke, Parkinson's disease, neonatal hypoxic-ischaemic encephalopathy, and cerebral palsy. Research here is aimed at improving recovery after brain injury, testing supportive therapies, and evaluating treatments that may reduce disability or improve quality of life.

• Acute stroke studies in patients with large vessel occlusion and large infarct cores
• Research in Parkinson's disease focused on long-term treatment safety and tolerability
• Studies in newborn brain injury evaluating innovative restorative approaches
• Trials addressing drooling and functional support in cerebral palsy

Together, these studies show a broad effort to improve care across both acute neurological emergencies and long-term neurodevelopmental conditions.

Beyond its main respiratory focus, the site also participates in studies across congenital, hereditary, and neonatal diseases and other complex conditions. These projects explore treatment effectiveness, safety, and supportive care in patients with diverse medical needs, including infections, inflammatory states, and cancer-related complications.

• Research in septic shock evaluating ways to improve organ function and critical care outcomes
• Studies in head and neck cancer and breast cancer focused on treatment optimization
• Trials involving patients with renal disease and other chronic comorbidities
• Investigations into long-term safety and real-world tolerability of emerging therapies

This diverse activity supports the hospital’s role as a broad clinical research center serving patients with both common and highly specialized conditions.